Skip to content
DataLookout
Menu

NCT06143553

Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer

StatusRecruiting
PhasePhase 3
Primary completion (estimated)

At risk: Primary completion moved at least 2 years later.

Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗

  1. Notable Primary completion pushed from Dec 2025 to Dec 31, 2027 Show 4 more changesShow less
    • Eligibility criteria expanded, about 42 words
    • Trial status changed: Unknown → Recruiting
    • Study completion pushed from Dec 2025 to Jun 30, 2028
    • Secondary endpoints: details revised at 1 of 4 entries
  2. Minor Changed Registry marked status Unknown; last known: Recruiting
  3. Notable Eligibility criteria expanded, about 5 wordsv2 Show 5 more changesShow less
    • Trial status: Recruiting to Unknown
    • Primary and study completion dates: Jul 2025 to Dec 2025
    • Start date: Oct 30, 2023 to Sep 25, 2023
    • Secondary endpoints: 5 to 4
    • Study title revised
  4. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Progression-Free-Survival
Timeframe: Randomization to measured PD or date of death from any cause(up to 24 months)

Secondary (4)

Objective response rate
Overall survival
Disease Control Rate
Incidence of adverse events

Arms and interventions

Paclitaxel Polymeric Micelles for InjectionExperimental

300mg/m2 of Paclitaxel Polymeric Micelles for Injection is intravenously administrated for ≥ 3 hours without special infusion device. The frequency of administration is once every 3 weeks (Q3W), and 3 weeks constitutes a treatment cycle.

The Doctor chooses the treatment(TPC)Active comparator

Control Group:The Doctor chooses the treatment(TPC):Eribulin Mesilate injection;Capecitabine Tablets;Gemcitabine Hydrochloride for Injection;Vinorelbine Tartrate Injection;Paclitaxel (albumin-bound). Eribulin Mesilate injection:on days 1 and 8 of the 21-day cycle, 1.4 mg/m2 , intravenous administration; Capecitabine Tablets: On days 1 to 14 of the 21-day cycle, 1000-1250mg/m2,oral administration, twice a day (once in the morning and once in the evening; Total daily dose 2000-2500mg/m2); Gemcitabine Hydrochloride for Injection: On days 1, 8 and 15 of the 28-day cycle, 800-1200mg/m2, intravenous administration; Vinorelbine Tartrate Injection: Every first day of the week, 25mg/m2,intravenous administration; Paclitaxel (albumin-bound): On day 1 of the 21-day cycle, 260mg/m2,intravenous administration for more than 30 minutes. Three weeks constituted one course of treatment.

Drugs: Paclitaxel Polymeric Micelles for Injection, Eribulin Mesilate injection, Capecitabine Tablets, Gemcitabine Hydrochloride for Injection, Vinorelbine Tartrate Injection, Paclitaxel (albumin-bound)

Sites

3 sites in 1 country